Boehringer Adds Yuhan’s First-In-Class Dual Agonist To NASH Portfolio

 
• By Jung Won Shin
  
liver
Yuhan Inks Second NASH License-Out Agreement • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from South Korea

More from Focus On Asia